Dare Bioscience Shares Rally After FDA OKs Xaciato
By Colin Kellaher
Shares of Dare Bioscience Inc. rose more than 35% in after-hours
trading Tuesday after the Food and Drug Administration approved
Xaciato for the treatment of bacterial vaginosis in females 12
years of age and older.
The approval marks the first FDA green light for the San Diego
company, which said it is in talks on strategic partnering and
other activities aimed at supporting a robust market introduction
of the drug in the U.S. next year.
Dare previously received FDA
qualified-infectious-disease-product designation for Xaciato, which
provides a five-year extension of the three years of market
exclusivity available to the product.
Dare shares, which closed Tuesday at $2.12, were recently
changing hands at $2.87, up 35.3%, in after-hours trading.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
December 07, 2021 17:33 ET (22:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.